Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COCA study of esomeprazole and Coca-Cola effects on capecitabine pharmacokinetics
NL-OMON27946Recruiting
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and esomeprazole in colorectal cancer (CRC) (3 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Primary pharmacokinetic endpoint. Started Feb 2018; status: recruiting.
02
Drugs
capecitabineesomeprazole
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON27946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27946.